Occurrence and management of neoplastic wounds in women
               with advanced breast cancer

Gozzo, Thais de Oliveira; Tahan, Fernanda Padovani; Andrade, Marceila de; Nascimento, Talita Garcia do; Prado, Maria Antonieta Spinoso

doi:10.5935/1414-8145.20140039

home Sumário navigate_before Anterior Atual Seguinte navigate_next

home Sumário

RESEARCH • Esc Anna Nery 18 (2) • Apr-Jun 2014 • https://doi.org/10.5935/1414-8145.20140039 linkcopy

Occurrence and management of neoplastic wounds in women with advanced breast cancer

Authorship SCIMAGO INSTITUTIONS RANKINGS

Abstracts

Objective: To characterize the socio-demographic profile of women with breast cancer who present neoplastic wounds, and to identify the dressings used most for treating these wounds.

Methods: This study has a quantitative approach, is cross-sectional and retrospective. The data was collected through a review of hospital records of women with breast cancer in the period 2000-2011.

Results: The sample was constituted of 62 women with a mean age of 55.4 years old; 75.8% were white, 55% had invasive ductal carcinoma and 27.4% were in clinical stage IIIb. Of the deaths recorded, 27% occurred in less than 1 year after the appearance of the wound. The symptoms recorded were pain (32.2%), bleeding (35%) and necrosis (21%). The products used were silver sulfadiazine (23%) and Essential Fatty Acid (EFA) (16.1%).

Conclusion: The results point to a lack of systematization of nursing care related to oncological wounds in this service.

Breast neoplasms; Palliative Care; Nursing; Wounds and injuries

Treatment used*	Total N%	When diagnosed N%	In the recurrence N%
Chemotherapy	55 88%	50%	38.7%
Radiotherapy	42 67.7%	46.8%	19.3%
Surgery	42 35.5%	25.8%	38.7%
Hormone therapy	24 38.7%	19.4%	12.9%

Characteristics*	Number	%
Bleeding	22	35.4
Pain	20	32.2
Necrosis	13	20.9
Exudate	10	16.1
Itching	7	11.3
Signs of infection	7	11.3
Odor	5	8.1
Desquamation	1	1.6

Products*	Number	%
Silver sulfadiazine	14	22.5
Essential fatty acid	10	16.1
Normal saline 0.9%	4	6.4
Vaseline	4	6.4
Hydrogel	2	3.2
Hydrocolloid dressing	2	3.2
Activated charcoal	2	3.2
Boric water	1	1.6
Cold cream	1	1.6
Hydrocolloid paste	1	1.6
Nebacetin^®	1	1.6
Cetoconazol	1	1.6
Metronidazole	1	1.6
Not reported	39	62.9

vertical_align_top show_chart

more_horiz close
- image
- translate
- link
- article
- vertical_align_top
- file_download
- show_chart
- image
- translate
- link
- article

location_on

Universidade Federal do Rio de Janeiro Rua Afonso Cavalcanti, 275, Cidade Nova, 20211-110 - Rio de Janeiro - RJ - Brasil, Tel: +55 21 3398-0952 e 3398-0941 - Rio de Janeiro - RJ - Brazil
E-mail: annaneryrevista@gmail.com

rss_feed Acompanhe os números deste periódico no seu leitor de RSS

[tfn01t06] ^*
HER-2/neu: Oncogene which determines the production of the HER-2 protein (Receptor 2 of the growth factor of the Human Epidermis);

[tfn02t06] ^**
Data collection finalized in September 2012.

Age	Number	%
30-40	14	22.6
41-50	12	19.4
51-60	13	21.0
61-70	13	21.0
Over 71	10	16.1
Color	Number	%
White	50	80.6
Black	6	9.7
Mixed race	5	8.1
Asian	1	1.6
Estrogen Receptor	Number	%
Positive	28	45.2
Negative	23	37.1
Not reported	11	17.7
Progesterone Receptor	Number	%
Positive	19	30.6
Negative	32	51.6
Not reported	11	17.7
HER-2/neu*	Number	%
Positive	25	40.3
Negative	24	38.7
Not reported	13	21.0
Medical Diagnosis	Number	%
Invasive Ductal Carcinoma	58	93.5
Others	4	6.4
Staging at diagnosis	Number	%
III a	9	14.5
IIIb	19	30.6
IV	18	29.0
Others	14	22.6
Not reported	2	3.2
Death**	Number	%
Yes	48	77.4
No	7	11.3
Lost to follow-up	7	11.3

Place of the wound	Number	%
Right breast	31	50
Left breast	26	42
Multiple lesions	5	8
Treatment used	Number	%
Chemotherapy	56	90.3
Radiotherapy	42	67.7
Surgery	42	67.7
Hormone therapy	23	37.1
Time of the appearance of the wound	Number	%
Diagnosis	28	45
Recurrence/Metastasis	14	22.5